MRNA Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$104.26 |
52 Week High | US$163.24 |
52 Week Low | US$62.55 |
Beta | 1.6 |
1 Month Change | 17.98% |
3 Month Change | 17.03% |
1 Year Change | -32.53% |
3 Year Change | -28.39% |
5 Year Change | 437.42% |
Change since IPO | 460.54% |
Recent News & Updates
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27Moderna: Counting On Pipeline Too Much
Feb 23Recent updates
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27Moderna: Counting On Pipeline Too Much
Feb 23Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World
Feb 16Moderna: Fade 2025 Outlook
Jan 15Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 29Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024
Nov 03Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate
Oct 18Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?
May 23Weak Statutory Earnings May Not Tell The Whole Story For Moderna (NASDAQ:MRNA)
Mar 03Earnings Working Against Moderna, Inc.'s (NASDAQ:MRNA) Share Price Following 28% Dive
Feb 25Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 48% Discount?
Feb 08Shareholder Returns
MRNA | US Biotechs | US Market | |
---|---|---|---|
7D | -6.9% | -2.1% | 0.5% |
1Y | -32.5% | 9.7% | 29.0% |
Return vs Industry: MRNA underperformed the US Biotechs industry which returned 9.7% over the past year.
Return vs Market: MRNA underperformed the US Market which returned 29% over the past year.
Price Volatility
MRNA volatility | |
---|---|
MRNA Average Weekly Movement | 8.7% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRNA's share price has been volatile over the past 3 months.
Volatility Over Time: MRNA's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 5,600 | Stephane Bancel | https://www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
MRNA fundamental statistics | |
---|---|
Market cap | US$39.92b |
Earnings (TTM) | -US$4.71b |
Revenue (TTM) | US$6.85b |
5.8x
P/S Ratio-8.5x
P/E RatioIs MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRNA income statement (TTM) | |
---|---|
Revenue | US$6.85b |
Cost of Revenue | US$9.54b |
Gross Profit | -US$2.69b |
Other Expenses | US$2.02b |
Earnings | -US$4.71b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -12.31 |
Gross Margin | -39.28% |
Net Profit Margin | -68.84% |
Debt/Equity Ratio | 0% |
How did MRNA perform over the long term?
See historical performance and comparison